Prague Lymphoma Lab – Laboratory of Experimental and Translational Hematology
Head: Pavel Klener
Prague node
HOME INSTITUTION
First Faculty of Medicine CU
RESEARCH PROGRAMME(S)
RP 5 - Translational oncology: Verification clinical studies of the proof-of-concept type
Make lymphoma research great again!
- Mission: Translational research of lymphomas and education of new generation of hematologists.
- Vision: Tailored thrapy of lymphoma patients based on risk stratification before therapy, and response adapted therapy.
The major goal of our group is our better understanding of molecular basis of aggressive lymphomas with focus on heterogeneity of lymphoma population and influence of microenvironment. Identification of novel druggable targets and rational treatment combinations, which will be validated in vitro on a panel of patient-validated cell lines and in vivo on a panel of patient-derived xenografts.
SELECTED PUBLICATIONS
- Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, Tuskova L, Hoferkova E, Mraz M, Helman K, Curik N, Machova Polakova K, Anděra L, Trněný M, Klener P. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood Adv. 2024 May 7:bloodadvances.2024012906. DOI: 10.1182/bloodadvances.2024012906
- Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion. Exp Hematol Oncol. 2024 Mar 25;13(1):34. DOI: 10.1186/s40164-024-00499-2
- Karolova J, Kazantsev D, Svatoň, M, Tušková, Forsterová, K, Maláriková, D, Benešová, K, Heizer, T, Dolníková, A, Klánová, M, Winkovska, L, Svobodová, K, Hojný, J, Krkavcová, E, Froňková, E, Zemanová, Z, Trněný, M, Klener, P. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. Am J Hematol. 2023 Oct ;98(10):1627-1636. DOI: 10.1002/ajh.27044
- Radek Jakša, Jana Karolová, Michael Svatoň, Dmitry Kazantsev, Martina Grajciarová, Eva Pokorná, Zbyněk Tonar, Magdalena Klánová, Lucie Winkowska, Diana Maláriková, Petra Vočková, Kristina Forsterová, Nicol Renešová, Alexandra Dolníková, Kristýna Nožičková, Pavel Dundr, Eva Froňková, Marek Trněný, Pavel Klener. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 2022 Sep;102(9):957-965. DOI: 10.1038/s41374-022-00784-w
- Magdalena Klanova, Dmitry Kazantsev, Eva Pokorna, Tomas Zikmund, Jana Karolova, Matej Behounek, Nicol Renesova, Dana Sovilj, Cristina D Kelemen, Karel Helman, Radek Jaksa, Ondrej Havranek, Ladislav Andera, Marek Trneny, Pavel Klener. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. Mol Cancer Ther. 2022 Jan;21(1):89-99. DOI: 10.1158/1535-7163.MCT-21-0511
COLLABORATION WITHIN THE NICR
Tomáš Etrych
(Prague node, Institute of Macromolecular Chemistry of the Czech Academy of Sciences)
Vladimír Kryštof
(Olomouc node, Faculty of Medicine PU in Olomouc)
SPECIALIZED EXPERTISE AND TECHNOLOGY
Single-cell RNA sequencing
In vivo proof-of-concept preclinical studies on patient-derived xenograft-bearing mice
SeaHorse analyzer
Hypoxic station
T-cells with chimeric antigen receptor (CAR T-cells) – in vitro and in vivo studies